Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018681 (
headache
)
56,091
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 37-year-old man, treated case of left temporal glioblastoma presented with
headache
, seizures, and progressive right-sided weakness with MRI evidence of recurrence. Exploratory Ga-
PSMA
PET/CT demonstrated
PSMA
expression in the recurrent lesion; it was decided to treat this patient with Lu-
PSMA
-617. After 3 cycles of Lu-
PSMA
-617, Ga-
PSMA
PET/CT showed significant reduction in
PSMA
uptake and regression in size of lesion on MRI with improvement in patient's symptoms and performance status. Lu-/Ga-
PSMA
theranostics has potential in patients with recurrent glioblastoma multiforme when other therapeutic options are not feasible.
...
PMID:177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. 3255 21
This first-in-human study investigated the safety, biodistribution and radiation dosimetry of the novel
18
F-labeled radiohybrid
prostate-specific membrane antigen
(rhPSMA) positron emission tomography (PET) imaging agent,
18
F-rhPSMA-7.3.
Methods:
Six healthy volunteer subjects (3 males, 3 females) underwent multiple whole-body PET acquisitions at scheduled time points up to 248 minutes after the administration of
18
F-rhPSMA-7.3 (mean activity 220; range, 210-228 MBq). PET scans were conducted in three separate sessions and subjects were encouraged to void between sessions. Blood and urine samples were collected for up to 4 hours post-injection to assess metabolite-corrected radioactivity in whole blood, plasma and urine. Quantitative measurements of
18
F radioactivity in volumes of interest (VOIs) over target organs were determined directly from the PET images at 8 time points and normalized time-activity concentration curves were generated. These normalized cumulated activities were then inputted into the OLINDA/EXM package to calculate the internal radiation dosimetry and the subjects' effective dose.
Results:
18
F-rhPSMA-7.3 was well tolerated. One adverse event (mild
headache
, not requiring medication) was considered possibly related to
18
F-rhPSMA-7.3: because of the temporal association with
18
F-rhPSMA-7.3 injection, a causal relationship could not be excluded. The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-hour voiding interval. The organs with the highest absorbed dose per unit of administered radioactivity were the adrenals (mean absorbed dose, 0.1835 mSv/MBq), the kidneys (mean absorbed dose, 0.1722 mSv/MBq), the submandibular glands (mean absorbed dose, 0.1479 mSv) and the parotid glands (mean absorbed dose, 0.1137 mSv/MBq). At the end of the first scanning session (mean time, 111 min post-injection), an average of 7.2% (range, 4.4-9.0%) of the injected radioactivity of
18
F-rhPSMA-7.3 was excreted into urine.
Conclusion:
The safety, biodistribution and internal radiation dosimetry
18
F-rhPSMA-7.3 are considered favorable for PET imaging.
...
PMID:Safety, biodistribution and radiation dosimetry of
18
F-rhPSMA-7.3 in healthy adult volunteers. 3306 38
